|
|
Background: Growing evidence from studies has shown that microRNA-196a (miR-196a) is correlated with treatment response and prognosis in Asian cancer patients. However, the studies reveal that the role of miR-196a is not totally consistent, making it rational to perform a meta-analysis to assess the prognostic value of miR-196a in cancers.
Methods: This meta-analysis was conducted by searching PubMed, Embase, the Cochrane library, China National Knowledge Infrastructure (CNKI), and Web of Science. Baseline characteristics and key statistics such as hazard ratio (HR), 95% confidence interval (CI), and p-value were extracted from studies investigating the association between clinical outcomes in Asian patients with cancers and the expression of miR-196a. The pooled HRs and CIs were calculated.
Results: 13 studies were included to assess the prognostic role of miR-196a in cancer patients. The pooled HR of higher miR-196a expression for overall survival (OS) was 3.08 (95% CI: 2.32 - 4.10, p < 0.001). For disease free survival (DFS) and recurrence free survival (RFS), the pooled HR is 3.83 (95% CI: 2.39 - 6.12, p < 0.001). No obvious between-study heterogeneity was shown among included studies. Hence, a fixed model was utilized. In our subgroup analysis, the results remain consistent. It shows that higher expression of miR-196a was both associated with poor OS and RFS/DFS in different kinds of cancers.
Conclusions: The present meta-analysis suggested that higher expression of miR-196a might predict poor prognosis in Asian cancer patients.
DOI: 10.7754/Clin.Lab.2016.160425
|
